Neoadjuvant therapy of imatinib in gastrointestinal stromal tumors and the timing of surgery.
- Author:
Yinan SHI
1
;
Xiaobo LIANG
Author Information
1. Department of minimally invasive Surgery, Shanxi Tumor Hospital, Taiyuan 030013, China. sxliangxiaobo100@163.com.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
Chemotherapy, Adjuvant;
Gastrointestinal Neoplasms;
Gastrointestinal Stromal Tumors;
Humans;
Imatinib Mesylate;
Neoadjuvant Therapy
- From:
Chinese Journal of Gastrointestinal Surgery
2015;18(4):313-315
- CountryChina
- Language:Chinese
-
Abstract:
Imatinib is the key medication for adjuvant therapy in gastrointestinal stromal tumors(GIST) and the first line therapy for patients with metastatic or recurrent GIST. Preoperative treatment with imatinib may improve R0 resection rate and provide the chance of metastasectomy for cytoreduction as well as prolonging patient's survival. We investigate the significance of neoadjuvant therapy of imatinib and the timing of surgery by reviewing clinical trials and consensus in recent years.
